Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-5552 in Recurrent Glioblastoma
NCT05557292Phase 1Terminated
- Sponsor
- Nicholas Butowski
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of RMC-5552 in glioblastoma (GBM) (4 cohorts), sponsored by Nicholas Butowski. Primary endpoints: Maximum Tolerated Dose up to 21 days, Recommended Phase II Dose up to 21 days and 8 more. Started Apr 2023; status: terminated.
02
Drugs
RMC-5552
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05557292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557292.